Folotyn for Non-Hodgkin's Lymphoma North Babylon NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

JOHN LOSCALZO, MD
(631) 666-6752
24 E Main Street
Bay Shore, NY
Daniel BUDMAN, MD
(516) 734-8958
450 Lakeville Road
New Hyde Park, NY
Tiffany A Troso Sandoval, MD
Garden City, NY
Laurence George Bilsky, MD
516-921-5533
40 Crossways Park Dr
Woodbury, NY
Edward Scott Valentine, MD
631-444-2200
15th Fl Rm 040,
Stony Brook, NY
Keriann Nickola Gray
(631) 261-4400
79 Middleville Rd
Northport, NY
IRUM CHAUDHRY, MD
(516) 965-1112
131 Marcellus Road
Mineola, NY
AGNIESZKA KOWALSKA, MD
(631) 444-7878
Stony Brook University Hospital
Stony Brook, NY
Steven Mark Sugarman, MD
631-863-5100
Stony Brook, NY
James P G Kwee, MD
516-248-1754
80 Lefferts Rd
Garden City, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles